Table 1.
The baseline characteristics of all qualified studies
| Study | Year | Region | Cancer subtype | Control features | Study design | Matching status | ADI assay (ELISA) | Sample size
|
Sample source | Adiponectin (µg/mL)
|
Age (years)
|
Male gender
|
BMI (kg/m2)
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | |||||||||
| Saetang et al25 (CRC) | 2016 | East Asia | CRC | W/o colonic polyps | Retrospective | NA | Thermo Fisher | 82 | 30 | Serum | 17.56 | 19.49 | 62.4 | 59.1 | NA | NA | NA | NA |
| Saetang et al25 (colon) | 2016 | East Asia | Colon | W/o colonic polyps | Retrospective | NA | Thermo Fisher | 52 | 30 | Serum | 15.65 | 19.49 | 62.4 | 59.1 | NA | NA | NA | NA |
| Saetang et al25 (rectum) | 2016 | East Asia | Rectum | W/o colonic polyps | Retrospective | NA | Thermo Fisher | 30 | 30 | Serum | 20.49 | 19.49 | 62.4 | 59.1 | NA | NA | NA | NA |
| Inamura et al29 (HPFS) | 2016 | USA | CRC | W/o CRC | Nested | Yes | ALPCO | 155 | 296 | Plasma | 5.00 | 5.60 | 66.2 | 66.2 | 1.000 | 1.000 | 26.1 | 25.3 |
| Inamura et al29 (NHS) | 2016 | USA | CRC | W/o CRC | Nested | Yes | ALPCO | 152 | 297 | Plasma | 7.90 | 8.20 | 58.5 | 66.2 | 0.000 | 0.000 | 25.2 | 24.7 |
| Zekri et al13 | 2015 | Middle East | CRC | W/o CRC | Retrospective | NA | RayBiotech | 34 | 29 | Serum | 11.28 | 6.59 | 41.3 | 66.2 | 0.588 | 0.552 | NA | NA |
| Demir et al37 | 2015 | Middle East | CRA | W/o CRC | Retrospective | NA | eBioscience | 32 | 30 | Serum | 8.57 | 9.70 | 53.5 | 66.2 | 0.625 | 0.500 | 29.1 | 26.1 |
| Chandler et al11 | 2015 | USA | CRC | W/o CRC | Nested | Yes | ALPCO | 275 | 275 | Plasma | 6.00 | 6.24 | 58.8 | 66.2 | 0.000 | 0.000 | 26.8 | 26.3 |
| Ochs-Balcom et al26 (white) | 2014 | USA | CRA | W/o CRA | Nested | NA | R&D | 217 | 650 | Plasma | 10.58 | 11.64 | 57.4 | 66.2 | 0.521 | 0.369 | 29.1 | 32.3 |
| Ochs-Balcom et al26 (AA) | 2014 | USA | CRA | W/o CRA | Nested | NA | R&D | 175 | 378 | Plasma | 7.76 | 8.02 | 58.2 | 66.2 | 0.406 | 0.241 | 31.7 | 32.3 |
| Aleksandrova et al5 (colon) | 2014 | Europe | Colon | W/o CRC | Nested | Yes | ALPCO | 794 | 794 | Serum | 6.70 | 6.80 | 58.6 | 66.2 | 0.530 | 0.530 | 26.8 | 26.3 |
| Aleksandrova et al5 (rectum) | 2014 | Europe | Rectum | W/o CRC | Nested | Yes | ALPCO | 466 | 466 | Serum | 6.50 | 6.80 | 58.0 | 66.2 | 0.457 | 0.457 | 26.6 | 26.4 |
| Aleksandrova et al40 (men) | 2014 | Europe | Colon | W/o CRC | Nested | Yes | ALPCO | 292 | 292 | Serum | 5.40 | 5.30 | 59.3 | 66.2 | 1.000 | 1.000 | 27.3 | 26.5 |
| Aleksandrova et al40 (women) | 2014 | Europe | Colon | W/o CRC | Nested | Yes | ALPCO | 370 | 370 | Serum | 8.30 | 8.40 | 58.6 | 66.2 | 0.000 | 0.000 | 26.4 | 26.1 |
| Abe Vicente et al43 | 2014 | USA | CRC | Healthy | Retrospective | NA | R&D | 39 | 40 | Serum | 4.60 | 3.60 | 61.0 | 66.2 | 0.590 | 0.650 | 23.9 | 23.9 |
| Song et al24 (men) | 2013 | USA | CRC | W/o CRC | Nested | Yes | Linco | 270 | 519 | Plasma | 4.99 | 5.32 | 65.8 | 66.2 | 1.000 | 1.000 | 26.2 | 25.4 |
| Song et al24 (women) | 2013 | USA | CRC | W/o CRC | Nested | Yes | Linco | 346 | 686 | Plasma | 8.04 | 8.19 | 59.0 | 66.2 | 0.000 | 0.000 | 26.0 | 25.5 |
| Danese et al38 (men) | 2013 | Europe | CRA | W/o CRC | Retrospective | Yes | Mediagnost | 21 | 26 | Plasma | 7.86 | 5.83 | 63.0 | 66.2 | 0.525 | 0.650 | 26.0 | 26.0 |
| Danese et al38 (women) | 2013 | Europe | CRA | W/o CRC | Retrospective | Yes | Mediagnost | 19 | 14 | Plasma | 11.81 | 9.89 | NA | NA | NA | NA | NA | NA |
| Kemik et al8 (colon) | 2012 | Middle East | Colon | Healthy | Retrospective | NA | Linco | 32 | 40 | Serum | 4.80 | 6.50 | 49.5 | 40.4 | 0.563 | 0.550 | 15.9 | 21.5 |
| Kemik et al8 (rectum) | 2012 | Middle East | Rectum | Healthy | Retrospective | NA | Linco | 35 | 40 | Serum | 4.70 | 6.50 | 44.8 | 40.4 | 0.543 | 0.550 | 16.2 | 21.5 |
| Ho et al30 | 2012 | USA | CRC | W/o CRC | Nested | NA | Millipore | 457 | 834 | Plasma | 27.20 | 29.10 | NA | NA | NA | NA | NA | NA |
| Hillenbrand et al31 (men) | 2012 | Europe | CRC | Healthy | Retrospective | NA | Millipore | 42 | 30 | Serum | 14.20 | 11.80 | 65.5 | 46.0 | 1.000 | 1.000 | 27.2 | NA |
| Hillenbrand et al31 (women) | 2012 | Europe | CRC | Healthy | Retrospective | NA | Millipore | 25 | 30 | Serum | 21.90 | 22.50 | 66.0 | 44.0 | 0.000 | 0.000 | 26.4 | NA |
| Gulcelik et al32 | 2012 | Middle East | Colon | W/o cancer | Retrospective | NA | B-Bridge | 27 | 40 | Serum | 9.51 | 13.91 | 52.1 | 52.4 | 0.593 | 0.250 | 26.8 | 26.8 |
| Chen et al39 (E) | 2012 | East Asia | CRC | W/o colonic polyps | Retrospective | NA | Adlitteram | 71 | 102 | Plasma | 10.10 | 13.20 | 62.1 | 58.3 | 1.000 | 1.000 | 23.5 | 22.9 |
| Chen et al39 (A) | 2012 | East Asia | CRC | W/o colonic polyps | Retrospective | NA | Adlitteram | 94 | 102 | Plasma | 9.30 | 13.20 | 61.8 | 58.3 | 1.000 | 1.000 | 22.4 | 22.9 |
| Aleksandrova et al41 (colon) | 2012 | Europe | Colon | W/o CRC | Nested | Yes | ALPCO | 755 | 755 | Serum | 6.71 | 6.84 | 58.6 | 58.6 | 0.542 | 0.542 | 26.9 | 26.3 |
| Aleksandrova et al41 (rectum) | 2012 | Europe | Rectum | W/o CRC | Nested | Yes | ALPCO | 451 | 451 | Serum | 6.38 | 6.79 | 58.0 | 58.0 | 0.452 | 0.452 | 26.5 | 26.4 |
| Al-Harithy and Al-Zahrani42 (men) | 2012 | Middle East | CRC | Healthy | Retrospective | Yes | ALPCO | 31 | 30 | Serum | 5.59 | 6.38 | 55.0 | 49.0 | 1.000 | 1.000 | 24.8 | 29.1 |
| Al-Harithy and Al-Zahrani42 (women) | 2012 | Middle East | CRC | Healthy | Retrospective | Yes | ALPCO | 29 | 30 | Serum | 4.47 | 8.89 | 53.5 | 52.0 | 0.000 | 0.000 | 26.8 | 28.8 |
| Gialamas et al34 | 2011 | Europe | CRC | Healthy | Retrospective | Yes | RI | 104 | 208 | Serum | 9.45 | 10.38 | 69.8 | 69.1 | 0.625 | 0.625 | NA | NA |
| Chronis et al10 (NOAA) | 2011 | Europe | CRA | W/o CRA | Retrospective | NA | Linco | 22 | 138 | Serum | 10.90 | 10.20 | 65.1 | 63.5 | 0.545 | 0.587 | 26.4 | 27.4 |
| Chronis et al10 (AA) | 2011 | Europe | CRA | W/o CRA | Retrospective | NA | Linco | 46 | 138 | Serum | 11.20 | 10.20 | 66.2 | 63.5 | 0.565 | 0.587 | 27.1 | 27.4 |
| Catalan et al7 | 2011 | Europe | Colon | Healthy | Retrospective | NA | R&D | 11 | 18 | Plasma | 4.07 | 8.09 | 66.0 | 44.0 | NA | NA | 26.9 | 29.3 |
| Al Khaldi et al12 | 2011 | Middle East | Colon | Healthy | Retrospective | Yes | Linco | 58 | 68 | Plasma | 8.60 | 4.10 | 53.0 | 60.0 | 0.500 | 0.500 | 27.9 | 26.0 |
| Yamaji et al22 (men) | 2010 | East Asia | CRA | W/o CRA | Nested | NA | NA | 523 | 480 | Plasma | 3.98 | 4.37 | NA | NA | 1.000 | 1.000 | NA | NA |
| Yamaji et al22 (women) | 2010 | East Asia | CRA | W/o CRA | Nested | NA | NA | 255 | 255 | Plasma | 6.81 | 7.36 | NA | NA | 0.000 | 0.000 | NA | NA |
| Nakajima et al27 | 2010 | East Asia | CRA | W/o CRC | Retrospective | Yes | Otsuka | 115 | 115 | Serum | 8.90 | 8.90 | 63.7 | 63.5 | 0.600 | 0.600 | 22.9 | 23.1 |
| Kemik et al28 | 2010 | Middle East | Colon | Healthy | Retrospective | NA | Linco | 126 | 36 | Serum | 4.30 | 6.50 | 43.5 | 40.4 | 0.421 | 0.444 | NA | NA |
| Gonullu et al33 | 2010 | Middle East | CRC | Healthy | Retrospective | NA | Bio-Source | 36 | 37 | Serum | 5.50 | 6.20 | 56.6 | 51.0 | 0.500 | 0.541 | 27.2 | 27.0 |
| Erarslan et al36 (CRA) | 2009 | Middle East | CRA | W/o colonic polyps | Retrospective | NA | RayBiotech | 31 | 50 | Serum | 7.40 | 9.20 | 63.0 | 59.0 | 0.548 | 0.540 | 26.0 | 29.2 |
| Erarslan et al36 (CRC) | 2009 | Middle East | CRC | W/o colonic polyps | Retrospective | NA | RayBiotech | 23 | 50 | Serum | 7.10 | 9.20 | 57.0 | 59.0 | 0.609 | 0.540 | 24.6 | 29.2 |
| Stocks et al9 (men) | 2008 | Europe | CRC | W/o cancer | Nested | Yes | R&D | 125 | 245 | Plasma | 7.00 | 6.60 | 59.8 | NA | 1.000 | 1.000 | NA | NA |
| Stocks et al9 (women) | 2008 | Europe | CRC | W/o cancer | Nested | Yes | R&D | 181 | 350 | Plasma | 11.40 | 11.40 | 59.7 | NA | 0.000 | 0.000 | NA | NA |
| Ferroni et al35 | 2007 | Europe | CRC | W/o CRC | Retrospective | NA | BioVendor | 60 | 35 | Serum | 8.30 | 13.10 | 64.0 | 63.0 | 0.517 | 0.514 | NA | NA |
| Wei et al23 | 2005 | USA | CRC | W/o CRC | Nested | Yes | Linco | 179 | 177 | Plasma | 7.40 | 7.80 | 66.6 | 66.5 | 1.000 | 1.000 | 25.9 | 25.4 |
| Otake et al6 | 2005 | East Asia | CRA | W/o colonic polyps | Retrospective | NA | Otsuka | 51 | 52 | Plasma | 7.00 | 10.60 | 59.0 | 58.0 | 0.686 | 0.654 | 23.6 | 22.8 |
| Study | Year | WHR
|
WC (cm)
|
DM
|
Physical activity (h/week)
|
Physical inactivity
|
Smoking
|
Family history
|
Glucose (mmol/L)
|
Insulin (µ U/mL)
|
CRP (mg/L)
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | ||
| Saetang et al25 (CRC) | 2016 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Saetang et al25 (colon) | 2016 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Saetang et al25 (rectum) | 2016 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Inamura et al29 (HPFS) | 2016 | NA | NA | NA | NA | NA | NA | 32.1 | 30.4 | NA | NA | 0.610 | 0.550 | 0.790 | 0.860 | NA | NA | NA | NA | NA | NA |
| Inamura et al29 (NHS) | 2016 | NA | NA | NA | NA | NA | NA | 15.2 | 14.8 | NA | NA | 0.560 | 0.510 | 0.840 | 0.850 | NA | NA | NA | NA | NA | NA |
| Zekri et al13 | 2015 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Demir et al37 | 2015 | NA | NA | 102.8 | 95.0 | 0.000 | 0.000 | NA | NA | NA | NA | NA | NA | NA | NA | 5.48 | 5.47 | 12.05 | 6.93 | NA | NA |
| Chandler et al11 | 2015 | NA | NA | NA | NA | NA | NA | 15.4 | 16.5 | NA | NA | 0.098 | 0.113 | 0.120 | 0.098 | NA | NA | NA | NA | NA | NA |
| Ochs-Balcom et al26 (white) | 2014 | 0.92 | 0.90 | 99.6 | 95.1 | 0.078 | 0.086 | NA | NA | NA | NA | 0.553 | 0.489 | 0.267 | 0.246 | 4.79 | 4.73 | 7.70 | 6.20 | 3.00 | 2.30 |
| Ochs-Balcom et al26 (AA) | 2014 | 0.97 | 0.93 | 105.0 | 104.1 | 0.252 | 0.226 | NA | NA | NA | NA | 0.703 | 0.608 | 0.166 | 0.238 | 5.55 | 5.22 | 15.30 | 9.90 | 2.40 | 2.30 |
| Aleksandrova et al5 (colon) | 2014 | NA | NA | 90.7 | 88.5 | NA | NA | NA | NA | 0.152 | 0.116 | 0.237 | 0.215 | NA | NA | NA | NA | NA | NA | NA | NA |
| Aleksandrova et al5 (rectum) | 2014 | NA | NA | 90.4 | 89.7 | NA | NA | NA | NA | 0.146 | 0.133 | 0.281 | 0.288 | NA | NA | NA | NA | NA | NA | NA | NA |
| Aleksandrova et al40 (men) | 2014 | 0.96 | 0.94 | 97.8 | 94.8 | NA | NA | NA | NA | 0.178 | 0.147 | 0.281 | 0.253 | NA | NA | NA | NA | NA | NA | 2.80 | 1.90 |
| Aleksandrova et al40 (women) | 2014 | 0.81 | 0.81 | 84.3 | 82.6 | NA | NA | NA | NA | 0.127 | 0.097 | 0.200 | 0.170 | NA | NA | NA | NA | NA | NA | 3.30 | 2.70 |
| Abe Vicente et al43 | 2014 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Song et al24 (men) | 2013 | 0.96 | 0.94 | 98.0 | 95.3 | NA | NA | 31.9 | 31.0 | NA | NA | 0.050 | 0.049 | 0.196 | 0.139 | NA | NA | NA | NA | 1.34 | 1.13 |
| Song et al24 (women) | 2013 | 0.79 | 0.78 | 81.0 | 79.5 | NA | NA | 16.6 | 16.9 | NA | NA | 0.145 | 0.123 | 0.139 | 0.120 | NA | NA | NA | NA | 1.52 | 1.67 |
| Danese et al38 (men) | 2013 | NA | NA | 97.5 | 95.9 | NA | NA | NA | NA | NA | 0.294 | NA | NA | NA | NA | 5.53 | 5.38 | NA | NA | 1.90 | 1.80 |
| Danese et al38 (women) | 2013 | NA | NA | 94.2 | 81.1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Kemik et al8 (colon) | 2012 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 9.10 | 3.50 |
| Kemik et al8 (rectum) | 2012 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 9.10 | 3.50 |
| Ho et al30 | 2012 | NA | NA | NA | NA | 0.000 | 0.000 | NA | NA | 0.296 | 0.294 | 0.540 | 0.458 | 0.182 | 0.155 | NA | NA | 6.50 | 5.30 | NA | NA |
| Hillenbrand et al31 (men) | 2012 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Hillenbrand et al31 (women) | 2012 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Gulcelik et al32 | 2012 | NA | NA | NA | NA | 0.000 | 0.000 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Chen et al39 (E) | 2012 | 0.89 | 0.86 | NA | NA | 0.000 | 0.000 | NA | NA | 0.690 | 0.725 | 0.380 | 0.304 | NA | NA | NA | NA | NA | NA | NA | NA |
| Chen et al39 (A) | 2012 | 0.85 | 0.86 | NA | NA | 0.000 | 0.000 | NA | NA | 0.777 | 0.725 | 0.415 | 0.304 | NA | NA | NA | NA | NA | NA | NA | NA |
| Aleksandrova et al41 (colon) | 2012 | 0.88 | 0.87 | 90.4 | 88.1 | NA | NA | NA | NA | 0.144 | 0.114 | 0.567 | 0.538 | NA | NA | NA | NA | NA | NA | 3.10 | 2.30 |
| Aleksandrova et al41 (rectum) | 2012 | 0.89 | 0.88 | 90.4 | 89.9 | NA | NA | NA | NA | 0.151 | 0.131 | 0.609 | 0.603 | NA | NA | NA | NA | NA | NA | 2.40 | 2.30 |
| Al-Harithy and Al-Zahrani42 (men) | 2012 | 1.23 | 0.95 | 72.6 | 75.7 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Al-Harithy and Al-Zahrani42 (women) | 2012 | 0.95 | 1.01 | 61.0 | 84.6 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Gialamas et al34 | 2011 | 1.01 | 0.94 | NA | NA | 0.279 | 0.173 | NA | NA | 0.279 | 0.178 | 0.490 | 0.519 | NA | NA | NA | NA | NA | NA | NA | NA |
| Chronis et al10 (NOAA) | 2011 | NA | NA | 99.3 | 99.9 | 0.000 | 0.000 | NA | NA | NA | NA | 0.318 | 0.304 | NA | NA | 5.34 | 5.58 | 5.80 | 5.90 | NA | NA |
| Chronis et al10 (AA) | 2011 | NA | NA | 99.2 | 99.9 | 0.000 | 0.000 | NA | NA | NA | NA | 0.261 | 0.304 | NA | NA | 5.70 | 5.58 | 7.10 | 5.90 | NA | NA |
| Catalan et al7 | 2011 | NA | NA | NA | NA | 0.000 | 0.000 | NA | NA | NA | NA | NA | NA | NA | NA | 6.06 | 5.50 | 3.80 | 12.00 | 11.96 | 4.31 |
| Al Khaldi et al12 | 2011 | NA | NA | 106.0 | 102.5 | 0.000 | 0.000 | NA | NA | NA | NA | NA | NA | NA | NA | 7.30 | 5.80 | 10.40 | 11.00 | NA | NA |
| Yamaji et al22 (men) | 2010 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 0.138 | 0.135 | NA | NA | NA | NA | NA | NA | NA | NA |
| Yamaji et al22 (women) | 2010 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 0.216 | 0.102 | NA | NA | NA | NA | NA | NA | NA | NA |
| Nakajima et al27 | 2010 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Kemik et al28 | 2010 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 9.80 | 3.50 |
| Gonullu et al33 | 2010 | 0.92 | 0.93 | NA | NA | 0.000 | 0.000 | NA | NA | NA | NA | NA | NA | NA | NA | 5.33 | 5.15 | 10.50 | 6.10 | NA | NA |
| Erarslan et al36 (CRA) | 2009 | NA | NA | 94.0 | 102.0 | 0.000 | 0.000 | NA | NA | NA | NA | NA | NA | NA | NA | 5.34 | 5.24 | 8.60 | 12.90 | NA | NA |
| Erarslan et al36 (CRC) | 2009 | NA | NA | 84.0 | 102.0 | 0.000 | 0.000 | NA | NA | NA | NA | NA | NA | NA | NA | 5.12 | 5.24 | 9.70 | 12.90 | NA | NA |
| Stocks et al9 (men) | 2008 | NA | NA | NA | NA | 0.000 | 0.000 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Stocks et al9 (women) | 2008 | NA | NA | NA | NA | 0.000 | 0.000 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Ferroni et al35 | 2007 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Wei et al23 | 2005 | 0.95 | 0.94 | 97.0 | 95.0 | NA | NA | 28.6 | 28.9 | NA | NA | 0.051 | 0.054 | 0.207 | 0.126 | NA | NA | NA | NA | NA | NA |
| Otake et al6 | 2005 | NA | NA | NA | NA | 0.000 | 0.000 | NA | NA | NA | NA | NA | NA | NA | NA | 5.83 | 5.11 | 8.50 | 6.10 | NA | NA |
Abbreviations: ADI, adiponectin; ELISA, enzyme-linked immunosorbent assay; CRC, colorectal cancer; HPFS, Health Professionals Follow-up Study; NHS, Nurses’ Health Study; CRA, colorectal adenoma; AA, advanced adenoma; NOAA, without advanced adenoma; W/o, without; BMI, body mass index; WHR, waist–hip ratio; WC, waist circumference; DM, diabetes mellitus; CRP, C-reactive protein; NA, not available.